A group of economist has entered the scene within the Supreme Court and the current case made by the Federal Trade Commission against the so-called pay-for-delay deals in which brand-name drug makers pay their generic counterparts to stay off the shelves for some time. An amicus brief was filed last Friday on behalf of the economists arguing that the FTC does not present sufficient economic evidence to back its claims that pay-for-delay deals hurt consumers. Additionally, the economists are claiming the FTC’s definition of pay-for-delay, or reverse payments, is too broad, and that reverse payments are economically the same as other patent settlements in other markets.
Featured News
Deutsche Boerse Nears €5.3 Billion Deal for Allfunds
Jan 20, 2026 by
CPI
Irish Appliance Maker Probed Over Alleged Price-Fixing Practices
Jan 20, 2026 by
CPI
UK Regulator Accuses Meta of Allowing Illegal Gambling Ads
Jan 20, 2026 by
CPI
Michigan Is Latest Battleground in Fight Over Growth of AI Data Centers
Jan 20, 2026 by
CPI
Enterprise AI Gets Real as Davos 2026 Focuses on Agents
Jan 20, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – CRESSE Insights
Dec 16, 2025 by
CPI
Learning from Divergence: The Role of Cross-Country Comparisons in the Evaluation of the DMA
Dec 16, 2025 by
Federico Bruni
New Regulatory Tools for the EU Foreign Direct Investment Screening and Foreign Subsidies Regulation
Dec 16, 2025 by
Ioannis Kokkoris
“Suite Dreams”: Market Definition and Complementarity in the Digital Age
Dec 16, 2025 by
Romain Bizet & Matteo Foschi
The Interaction Between Competition Policy and Consumer Protection: Institutional Design, Behavioral Insights, and Emerging Challenges in Digital Markets
Dec 16, 2025 by
Alessandra Tonazzi